Rangeley Capital LLC Invests $325,000 in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Rangeley Capital LLC bought a new position in Lifecore Biomedical, Inc. (NASDAQ:LFCR - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 43,700 shares of the company's stock, valued at approximately $325,000. Rangeley Capital LLC owned about 0.12% of Lifecore Biomedical at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LFCR. DCF Advisers LLC lifted its position in shares of Lifecore Biomedical by 87.2% in the fourth quarter. DCF Advisers LLC now owns 539,989 shares of the company's stock valued at $4,012,000 after acquiring an additional 251,511 shares in the last quarter. 272 Capital LP raised its stake in Lifecore Biomedical by 511.1% in the 3rd quarter. 272 Capital LP now owns 143,480 shares of the company's stock valued at $707,000 after purchasing an additional 120,002 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Lifecore Biomedical by 14.7% in the 4th quarter. Geode Capital Management LLC now owns 685,746 shares of the company's stock valued at $5,097,000 after purchasing an additional 88,061 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Lifecore Biomedical by 2,640.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 54,399 shares of the company's stock worth $268,000 after purchasing an additional 52,414 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in shares of Lifecore Biomedical in the third quarter valued at about $207,000. Institutional investors and hedge funds own 83.36% of the company's stock.

Insider Transactions at Lifecore Biomedical

In other Lifecore Biomedical news, CEO Paul Josephs acquired 17,000 shares of the stock in a transaction that occurred on Wednesday, January 8th. The stock was bought at an average cost of $5.74 per share, for a total transaction of $97,580.00. Following the completion of the transaction, the chief executive officer now owns 559,717 shares of the company's stock, valued at approximately $3,212,775.58. The trade was a 3.13 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 32.20% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Stephens restated an "equal weight" rating and set a $6.00 price target on shares of Lifecore Biomedical in a research report on Friday, January 3rd.

Lifecore Biomedical Trading Up 8.5 %

NASDAQ:LFCR traded up $0.44 during trading hours on Tuesday, hitting $5.54. The company had a trading volume of 164,306 shares, compared to its average volume of 221,807. Lifecore Biomedical, Inc. has a 1 year low of $3.68 and a 1 year high of $7.99. The company has a market cap of $204.93 million, a P/E ratio of -9.88 and a beta of 0.80. The company has a 50-day moving average of $6.16 and a 200 day moving average of $6.26. The company has a current ratio of 2.32, a quick ratio of 1.21 and a debt-to-equity ratio of 9.21.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last announced its quarterly earnings data on Thursday, April 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.05). Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. The firm had revenue of $35.15 million during the quarter, compared to analysts' expectations of $33.23 million. Sell-side analysts expect that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current year.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.